BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Synageva BioPharma 

Corporate Offices
128 Spring Street, Suite 520
Lexington  Massachusetts  02421  U.S.A.
Phone: 781-890-1111 Fax: 781-890-1114


Synageva BioPharma is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical need. Our lead program, SBC-102, an enzyme replacement therapy for LAL Deficiency, is currently being evaluated in global Phase I/II clinical trials. SBC-102 has been granted orphan designations by the U.S. Food and Drug Administration (“FDA”) and the European Medicines Agency and fast track designation by the FDA. Synageva has several protein therapeutics focused on life threatening conditions in its pipeline. The Company has assembled a team with a proven record of bringing orphan therapies to patients.

 Key Statistics

Ownership: Public

Web Site: Synageva BioPharma
Symbol: GEVA

 Company News
Synageva BioPharma (GEVA) Submits Kanuma (Sebelipase Alfa) Application For LAL Deficiency In Japan 5/27/2015 6:38:05 AM
Alexion (ALXN) Plunks Down $8.4 Billion for Synageva BioPharma (GEVA), As Dealmaking Roars 5/6/2015 5:50:36 AM
Synageva BioPharma (GEVA) Reports First Quarter 2015 Financial Results and Provides General Business Updates 4/29/2015 12:25:18 PM
Synageva BioPharma (GEVA) Submits Kanuma (Sebelipase Alfa) Application For LAL Deficiency In Mexico 3/30/2015 11:58:02 AM
1,075 New Jobs to be Added by 11 Life Science Firms in Massachusetts: Amgen (AMGN), Alnylam (ALNY), Biogen Idec, Inc. (North Carolina) (BIIB), GE Healthcare Bio-Sciences, Quest Diagnostics (DGX), Alkermes (ALKS), Baxter Healthcare (BAX), Merrimack (MACK), Synageva BioPharma (GEVA), Philips Electronics, SMC 3/19/2015 6:51:59 AM
Synageva BioPharma (GEVA) Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2/27/2015 10:29:19 AM
Synageva BioPharma (GEVA) Reports 2014 Full Year Financial Results 2/27/2015 7:20:13 AM
Synageva BioPharma (GEVA) To Present At The Cowen and Company Health Care Conference 2/25/2015 10:28:22 AM
FDA Accepts BLA Filing For Synageva BioPharma (GEVA)'s Kanuma (Sebelipase Alfa); Grants Priority Review And Assigns Pdufa Date 2/23/2015 6:41:04 AM
Synageva BioPharma (GEVA) To Host 2014 Fourth Quarter And Full Year Financial Results Conference Call On February 26 2/19/2015 11:51:18 AM